Skip to main content

Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction.

Publication ,  Journal Article
Redfield, MM; Anstrom, KJ; Levine, JA; Koepp, GA; Borlaug, BA; Chen, HH; LeWinter, MM; Joseph, SM; Shah, SJ; Semigran, MJ; Felker, GM ...
Published in: N Engl J Med
December 10, 2015

BACKGROUND: Nitrates are commonly prescribed to enhance activity tolerance in patients with heart failure and a preserved ejection fraction. We compared the effect of isosorbide mononitrate or placebo on daily activity in such patients. METHODS: In this multicenter, double-blind, crossover study, 110 patients with heart failure and a preserved ejection fraction were randomly assigned to a 6-week dose-escalation regimen of isosorbide mononitrate (from 30 mg to 60 mg to 120 mg once daily) or placebo, with subsequent crossover to the other group for 6 weeks. The primary end point was the daily activity level, quantified as the average daily accelerometer units during the 120-mg phase, as assessed by patient-worn accelerometers. Secondary end points included hours of activity per day during the 120-mg phase, daily accelerometer units during all three dose regimens, quality-of-life scores, 6-minute walk distance, and levels of N-terminal pro-brain natriuretic peptide (NT-proBNP). RESULTS: In the group receiving the 120-mg dose of isosorbide mononitrate, as compared with the placebo group, there was a nonsignificant trend toward lower daily activity (-381 accelerometer units; 95% confidence interval [CI], -780 to 17; P=0.06) and a significant decrease in hours of activity per day (-0.30 hours; 95% CI, -0.55 to -0.05; P=0.02). During all dose regimens, activity in the isosorbide mononitrate group was lower than that in the placebo group (-439 accelerometer units; 95% CI, -792 to -86; P=0.02). Activity levels decreased progressively and significantly with increased doses of isosorbide mononitrate (but not placebo). There were no significant between-group differences in the 6-minute walk distance, quality-of-life scores, or NT-proBNP levels. CONCLUSIONS: Patients with heart failure and a preserved ejection fraction who received isosorbide mononitrate were less active and did not have better quality of life or submaximal exercise capacity than did patients who received placebo. (Funded by the National Heart, Lung, and Blood Institute; ClinicalTrials.gov number, NCT02053493.).

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

N Engl J Med

DOI

EISSN

1533-4406

Publication Date

December 10, 2015

Volume

373

Issue

24

Start / End Page

2314 / 2324

Location

United States

Related Subject Headings

  • Walking
  • Vasodilator Agents
  • Stroke Volume
  • Quality of Life
  • Peptide Fragments
  • Natriuretic Peptide, Brain
  • Motor Activity
  • Middle Aged
  • Male
  • Isosorbide Dinitrate
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Redfield, M. M., Anstrom, K. J., Levine, J. A., Koepp, G. A., Borlaug, B. A., Chen, H. H., … NHLBI Heart Failure Clinical Research Network, . (2015). Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med, 373(24), 2314–2324. https://doi.org/10.1056/NEJMoa1510774
Redfield, Margaret M., Kevin J. Anstrom, James A. Levine, Gabe A. Koepp, Barry A. Borlaug, Horng H. Chen, Martin M. LeWinter, et al. “Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction.N Engl J Med 373, no. 24 (December 10, 2015): 2314–24. https://doi.org/10.1056/NEJMoa1510774.
Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH, et al. Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2015 Dec 10;373(24):2314–24.
Redfield, Margaret M., et al. “Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction.N Engl J Med, vol. 373, no. 24, Dec. 2015, pp. 2314–24. Pubmed, doi:10.1056/NEJMoa1510774.
Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH, LeWinter MM, Joseph SM, Shah SJ, Semigran MJ, Felker GM, Cole RT, Reeves GR, Tedford RJ, Tang WHW, McNulty SE, Velazquez EJ, Shah MR, Braunwald E, NHLBI Heart Failure Clinical Research Network. Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2015 Dec 10;373(24):2314–2324.

Published In

N Engl J Med

DOI

EISSN

1533-4406

Publication Date

December 10, 2015

Volume

373

Issue

24

Start / End Page

2314 / 2324

Location

United States

Related Subject Headings

  • Walking
  • Vasodilator Agents
  • Stroke Volume
  • Quality of Life
  • Peptide Fragments
  • Natriuretic Peptide, Brain
  • Motor Activity
  • Middle Aged
  • Male
  • Isosorbide Dinitrate